Blueprint Genetics Laboratory located in Finland is a CLIA-certified (#99D2092375) laboratory and accredited by the College of American Pathologists (CAP #9257331) and by FINAS Finnish Accreditation Service, laboratory no. T292, accreditation requirement SFS-EN ISO 15189:2013. Detailed information about the scope is available on the FINAS website.
Blueprint Genetics Laboratory located in Marlborough, MA is a CLIA-certified (#22D0069726) laboratory and accredited by the College of American Pathologists (CAP #3733701).
We offer genetic testing globally covering North and South America, Europe, Australia and the Middle East.
Blueprint Genetics CES Platform and Blueprint Genetics WES Platform, manufactured by Blueprint Genetics Oy are CE marked in-vitro diagnostic medical devices. Samples that are sent to our Helsinki laboratory for whole-exome sequencing, panel, single-gene, or variant-specific testing are run on the CE marked in-vitro diagnostic medical devices.
Blueprint Genetic tests, such as panels run on a clinical exome platform, whole-exome sequencing assay, single-gene tests, and variant-specific tests, are not currently available for New York patient testing. Instructions to request permission from the New York Health Department can be found here.
Blueprint Genetics Finland licensure:
|#9257331||Apr 22, 2024|
|No. T292||Feb 2, 2024|
|#99D2092375||Apr 20, 2025|
|#CDS00800637||Apr 30, 2024|
|#34897||Aug 15, 2024|
|#LCO01312||Dec 30, 2024|
Blueprint Genetics Marlborough, MA licensure:
|#3733701||Feb 1, 2025|
|#22D0069726||Nov 16, 2024|
|#CDS-00800075||Mar 15, 2024|
|#25752A||Aug 15, 2024|
|#LCO00856||Dec 30, 2023|
|#5879||May 31, 2024|
Please see more information about our quality control and accreditation through the following link: